SI-BONE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.33 USD | -1.35% |
|
+7.96% | -26.97% |
| 05-07 | Morgan Stanley Trims Price Target on SI-Bone to $25 From $26, Keeps Overweight Rating | MT |
| 05-06 | Transcript : SI-BONE, Inc., Q1 2024 Earnings Call, May 06, 2024 |
Presentation Operator MessageOperator (Operator)Ladies and gentlemen, welcome to the SI-BONE 2...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
15.33
USD
Average target price
25.56
USD
Spread / Average Target
+66.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.97% | 632M | |
| +73.46% | 12.41B | |
| -15.61% | 8.23B | |
| +3.88% | 6.46B | |
| +14.69% | 5.5B | |
| +42.58% | 5.1B | |
| -19.05% | 4.05B | |
| -32.61% | 2.54B | |
| -0.74% | 1.99B | |
| +10.80% | 1.99B |
- Stock Market
- Equities
- SIBN Stock
- News SI-BONE, Inc.
- Transcript : SI-BONE, Inc. - Shareholder/Analyst Call